Nonclinical development plans from discovery to Phase I.
Development plan encompassing Phase I to III including NDA/NDS/MAA, reimbursement, medical affairs, and other commercial launch considerations.
Comprehensive development plan starting with discovery through to Phase III including key NDA/NDS/MAA, reimbursement, medical affairs, and other commercial launch considerations
Strategically designed scientific sections of a typical investor deck including product rationale, MOA, outline of development plans, nonclinical/clinical strategy etc.
Critical review of existing data to identify gaps and risks to approval, wtih mitigation strategies, for a FIH study to be conducted in any ICH region.
Authoring and/or critical review of FIH study Module 2 summaries and/or the IB to ensure strategic messaging is maintained, data requirements are met, gaps are justified, and risks are mitigated.
Expert critical analysis, review, and interpretation of regulator feedback with a summary of recommendations for next steps.
Critical review of existing CMC data and plans to develop a strategy for ensuring GMP readiness for clinical batches.
Authoring and/or critical review of FIH study Module 2 QOS to ensure phase appropriate requirements have been met and/or gaps and risks are identifed with mitigation strategies.
Critical analysis, review, and interpretation of regulator CMC feedback with a summary of recommendations for next steps
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.